The Fibrolamellar Cancer Foundation Establishes Partnership With Dialectic Therapeutics

Effort will support a new clinical trial for fibrolamellar carcinoma, a rare cancer that primarily impacts children and young adults

UF startup Dialectic Therapeutics, in partnership with the Fibrolamellar Cancer Foundation (FCF), will supply the experimental drug DT2216 for a clinical trial involving fibrolamellar patients. Under the agreement, FCF will fund the production of the DT2216 necessary to support the trial. The Foundation’s funding of the company’s manufacturing costs of the drug was crucial to ensure the launch of the new clinical trial this year.

Dialectic Therapeutics, Inc. is a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer. DT2216 is their first-in-class anticancer agent that targets a protein called BCL-XL, the most commonly over-expressed anti-apoptotic protein in cancer.

Read more about The Fibrolamellar Cancer Foundation Establishes Partnership With Dialectic Therapeutics.